You have 9 free searches left this month | to do more

empagliflozin

Empagliflozin is a drug used to treat Diabetes Mellitus, Type 2, Healthy, Heart Failure, and other conditions. Empagliflozin is being actively studied in 30 studies and prior, has been studied in 58.

Top SponsorsTop SitesTop Investigators
Boehringer IngelheimEast Coast Institute for Research, LLCAnton Borisov
EMSThe University of North Carolina at Chapel HillCHEOL WHAN LEE, M.D., Ph.D
Getz Pharma4. Military Clinical Hospital with Polyclinic SP ZOZCaroline M Kistorp
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Not yet recruiting
  • Atrial Fibrillation
  • +3 more
  • Empagliflozin
  • Placebo
  • Acquaviva Delle Fonti, Bari, Italy
    Miulli General Hospital
2021-04-01
Apr 1, 2021
O
Not yet recruiting
  • type1diabetes
  • Empagliflozin
  • Columbus, Ohio
    Ohio State University
2021-06-07
Jun 7, 2021
H
Recruiting
  • Glycogen Storage Disease Type IB
  • Empagliflozin
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
2021-08-08
Aug 8, 2021
C
Not yet recruiting
  • Glucose 6 Phosphatase Deficiency
  • Empagliflozin
  • Warsaw, Poland
    The Children's Memorial Health Institute
2021-06-18
Jun 18, 2021
B
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +2 more
  • Boston, Massachusetts
    Bringham Women Hospital
2021-10-04
Oct 4, 2021
U
Completed
  • End Stage Renal Disease
  • Empagliflozin
  • Placebo
  • Pisa, Italy
    Department of Endocrinology and Metabolism, University of Pisa
2021-09-13
Sep 13, 2021
C
Active, not recruiting
  • Type2 Diabetes
  • Cheonju, Chungcheongbuk-do, Korea, Republic of
    Chungbuk National University Hospital
2021-05-14
May 14, 2021
H
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Placebo
  • Hellerup, Denmark
    Center for Diabetes Research, Gentofte Hospital
2021-06-09
Jun 9, 2021
B
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +3 more
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
2021-10-07
Oct 7, 2021
U
Recruiting
  • Cardiovascular Diseases
  • Left Ventricular Hypertrophy
  • Empagliflozin
  • Placebo
  • Toronto, Ontario, Canada
  • +3 more
2021-06-14
Jun 14, 2021
H
Recruiting
  • Acromegaly
  • Cardiomyopathies
  • Empagliflozin
  • Shanghai, Shanghai, China
    Huashan Hospital
2020-08-17
Aug 17, 2020
B
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Aarhus, Denmark
    Department of Clinical Epidemiology - Aarhus Unversiteteshospita
2021-10-04
Oct 4, 2021
I
Completed
  • Cardiovascular Diseases
  • Empagliflozin
  • Placebos
  • New York, New York
    Mount Sinai Heart - Icahn School of Medicine at Mount Sinai
2021-03-02
Mar 2, 2021
N
Recruiting
  • Crohn's Disease
  • +2 more
  • Empagliflozin
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-10-14
Oct 14, 2021
H
Not yet recruiting
  • Type 2 Diabetes Mellitus
  • Seoul, Korea, Republic of
    Clinical Pharmacology, Asan Medical Center
2020-06-11
Jun 11, 2020
J
Completed
  • Diabetes Mellitus, Type 2
  • Diastolic Dysfunction
  • Empagliflozin
  • Placebo
  • Mainz, Germany
    Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Ze
2021-04-16
Apr 16, 2021
M
Active, not recruiting
  • NASH
  • +7 more
  • MET409 Active
  • +2 more
  • Fort Myers, Florida
  • +1 more
2021-05-28
May 28, 2021
R
Terminated
  • Diabetes Mellitus, Type 2
  • Acute Heart Failure
  • Empagliflozin
  • Placebo
  • Aachen, NRW, Germany
    Department of Internal Medicine I RWTH Aachen University Hospita
2021-03-09
Mar 9, 2021
P
Completed
  • Type 2 Diabetes Mellitus
  • Empagliflozin
  • Hydrochlorothiazide 25 mg
  • Neuss, North Rhine-Westphalia, Germany
    Profil Institut für Stoffwechselforschung GmbH
2020-07-13
Jul 13, 2020
Y
Completed
  • Heart Failure
  • Type II; Diabetes
  • Empagliflozin
  • Placebo Oral Capsule
  • New Haven, Connecticut
    Yale New Haven Hospital
2020-06-24
Jun 24, 2020
H
Completed
  • Patients
  • Hackensack, New Jersey
    Frontage Clinical Services Inc.
2020-03-24
Mar 24, 2020
B
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Mahlow, Germany
    Diabetes Agenda 2010 GmbH
2021-03-26
Mar 26, 2021
B
Completed
  • Diabetes Mellitus, Type 1
  • +2 more
  • Empagliflozin
  • +2 more
  • Toronto, Ontario, Canada
    Toronto General Hospital
2020-07-23
Jul 23, 2020